Jefferies cuts target for Alcon stock from USD 95.00 to USD 85.00

Published on 10/02/2026 at 12:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon lifted 2026 core earnings growth guidance to 12.00-15.00 percent. Alcon stock costs EUR 56.87 on October 2, 2026 versus EUR 56.89.

Watercolor illustration of a stylized human eye centered in wide panoramic composition. Iris rendered in intricate pastel rainbow patterns in lavender, mint, peach, gold with delicate ink linework and translucent watercolor washes — Alcon CH0432492467: Aquarell Illustration eines Auges mit bunten Iris Mustern in zarten Pastellfarben, Illustration mit AI erstellt.

Alcon (ISIN CH0432492467) stock was trading at EUR 56.87 at Lang & Schwarz on October 2, 2026 at 12:15 p.m. CEST, down 0.04 percent from the EUR 56.89 prior close. The latest analyst move came from Jefferies, which lowered its Alcon price target from USD 95.00 to USD 85.00 on September 22, 2026 while keeping a Buy rating, as Markets Insider reported. The cut puts valuation and product execution at the center of the next results discussion.

Jefferies trims its target

Jefferies analyst Michael Sarcone cited continued macroeconomic and competitive pressure in ophthalmology when reducing the target, according to Markets Insider. The target change contrasts with Alcon's operating outlook, which makes the gap between expectations and execution the key valuation issue.

Guidance remains tied to products

Alcon raised its 2026 core earnings growth guidance to 12.00-15.00 percent in constant currency after second-quarter results, while its core operating margin reached 20.60 percent, according to DK Street Journal. The same report said Alcon's surgical franchise grew 7.00 percent to USD 1.60 billion in the second quarter of 2026, while implantables grew 1.00 percent.

Alcon describes its business as two segments, Surgical and Vision Care, serving customers in more than 140 countries, according to its Investor Relations page. That mix makes the next quarterly update important for judging whether surgical equipment growth is translating into stronger implant sales.

November results set the next test

Zacks lists November 10, 2026 as Alcon's next earnings release date and gives a consensus estimate of USD 0.89 for earnings per share for the quarter ending September 2026, as Zacks reported. For comparison, Zacks said Alcon reported USD 0.84 per share for its latest quarter against a USD 0.77 consensus estimate, a 9.09 percent positive surprise. The next report therefore has two measurable checkpoints: delivery against USD 0.89 consensus earnings per share and progress from the 1.00 percent implantable growth rate.

Alcon stock holds near its daily base

At Lang & Schwarz, Alcon stock was trading at EUR 56.87 on October 2, 2026 at 12:15 p.m. CEST, versus the EUR 56.89 prior close at Lang & Schwarz on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Alcon stock.